Eisai’s and Merck Announces EU’s Marketing Approval of Lenvima (lenvatinib mesylate) for Hepatocellular carcinoma

 Eisai’s and Merck Announces EU’s Marketing Approval of Lenvima (lenvatinib mesylate) for Hepatocellular carcinoma

Eisai’s and Merck Announces EU’s Marketing Approval of Lenvima (lenvatinib mesylate) for Hepatocellular carcinoma

Shots: 
  • Post FDA approval, Lenvima receives EU approval for oral RTKi for the treatment of advanced or unresectable HCC
  • The approval is based on REFLECT study results: (Lenvima vs Sorafenib): mOS (13.6 vs 12.3 mos), mPFS (7.3 vs 3.6 mos); ORR (41% vs 12%); mTTP (7.4 vs 3.7mos)
  • Lenvima is approved for thyroid cancer in over 50 countries including in EU, Japan and the US, and in EU it is available as Kisplyx in combination with everolimus for the 2L treatment of renal cell carcinoma 

Click here to read full press release/ article | Ref: Eisai| Image:  PRNewswire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post